Clinical study for pyrrotinib combined with or without trastuzumab in the treatment of advanced her2-positive colorectal cancer
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2689432
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Pyrrotinib combined with trastuzumab:oral Pyrrotib maleate tablets, initial dose 400 mg/day, taken within 30 min after breakfast, once a day, continuous administration, 21 days per cycle. Trastuzumab for injection: intravenous infusion with an initial loading dose of 8mg/kg followed by 6mg/kg. The first infusion takes approximately 90 minutes.;Pyrrotinib alone:Oral Pyrrotib maleate tablets by initial dose of 400 mg/day, taken within 30 min after breakfast, once a day, continuous administration, 21 days per treatment cycle.
Primary outcome(s): objective response rate
Study Design: Non randomized control
创建时间：
2019-12-15
